GRFS Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeP/E ratio10.51Forward 8.48
EPS (TTM)$0.7143.5% YoY
Profit margin5.6%HEALTHCARE
Market cap$5.08BMid cap
Wall Street coverage
$10.87median target· current $6.98 (+55.7%)2 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- 8.48
- PEG ratio
- 0.23
- P/B
- 0.80
- P/S (TTM)
- 0.68
- EV/EBITDA
- 8.96
Profitability & growth
- ROE (TTM)
- 6.1%
- Operating margin
- 16.5%
- Revenue growth YoY
- -4.8%
- Dividend yield
- 2.3%
- Beta
- 1.17
Last earnings
Apr 30, 2026 · Estimate $0.15 · Reported $0.13
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
49 articles · sorted by datePage 1 of 3 · 49 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Grifols SA ADR
Company profileGrifols, SA is dedicated to obtaining, manufacturing, preparing and selling therapeutic products, mainly blood derivatives. The company is headquartered in Barcelona, Spain.
Classification
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- PARQUE EMPRESARIAL CAN SANT JOAN, BARCELONA, SPAIN
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$5.08B
Shares outstanding$680.6M
52W high$10.96
52W low$7.26
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent